Belpointe Asset Management’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Belpointe Asset Management’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13	Closed	-$104	–	3613
2023 Q1	$104	Hold	13	–	–	﹤0.01%	3719
2022 Q4	$152	Buy	+13	New	+$149	﹤0.01%	3654

Other funds holding DMK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Belpointe Asset Management's DMK Position: Q2 2023 in Review

Belpointe Asset Management sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2023, closing a stake of 13 shares — an estimated $104 sold.

Belpointe Asset Management first reported a position in DMK in Q4 2022 and held it in 2 quarters. The position peaked at $152 in Q4 2022. 22 funds tracked by Wall St. Rank hold DMK as of Q2 2023.

Belpointe Asset Management reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 13 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2023, an estimated $104.
Belpointe Asset Management first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2022 and held it in 2 quarters.
Belpointe Asset Management's DMK Pharmaceuticals Corporation Common Stock position peaked at $152 in Q4 2022.
22 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.